Navigation Links
Omni Bio Pharmaceutical Realigns Management
Date:2/24/2011

past two years, Dr. Dinarello has become one of the most honored researchers in the field of medicine having been awarded the 2009 Crafoord Prize by the Swedish Royal Academy of Sciences, the 2009 Albany Medical School Prize (the United States largest prize in medicine), the 2010 Paul Ehrlich Prize (Germany) and the 2010 Novartis Prize in Immunology.  Because of this extensive recognition for his contributions to the field of cytokine biology, Dr. Dinarello has become a very sought after speaker both domestically and internationally, and he has leveraged his relationships to the substantial benefit of Omni Bio.

Mr. Larkin further added, "Dr. Dinarello has generated significant interest in other immunological disease opinion leaders in determining the potential use of AAT as a potential therapy for additional immunological disease classifications.  As a result of his efforts and key relationships with investigators at well-known academic and research institutions, we are currently in discussions with a number of institutions on pursuing human clinical trials in other disease classifications.  We expect to provide further clarification on these prospective trials if preliminary commitments from the trial institutions are obtained."

About Omni Bio Pharmaceutical, Inc.

Omni Bio Pharmaceutical, Inc. (www.omnibiopharma.com) is an emerging biopharmaceutical company formed to acquire, license, and develop existing therapies for indications with substantial commercialization potential. Omni Bio's core technology and pipeline are based on issued and pending patents licensed from the University of Colorado Denver ("UCD") and a privately held corporation surrounding the broader therapeutic potential of currently marketed therapies. One of Omni Bio's lead development programs is evaluating an FDA-approved, off-patent drug, AAT, for the treatment
'/>"/>

SOURCE Omni Bio Pharmaceutical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
2. Par Pharmaceutical Reports Second Quarter 2008 Results
3. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
4. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
5. ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results
6. Huifeng Bio-Pharmaceutical (HFGB) Announces USD $1.1 Million Supply Agreement with DNP International Co. Inc.
7. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
8. VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference
9. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
10. Access Pharmaceuticals to Present at the Noble Financial Equity Conference
11. Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Nearly 20,000 medical professionals and healthcare leaders ... Clinical Lab Expo in Chicago ... diagnostic research and technology that will advance medicine and ... of Wednesday, July 30, more than 19,500 attendees had ... Lab Expo, with more than 10,000 of these attendees ...
(Date:7/31/2014)... the sound-processing part of the mouse brain in a ... trees in view. Their imaging technique allows zooming in ... and it enabled the team to watch brain cells ... results, which represent a step toward better understanding how ... the journal Neuron . , In the past, ...
(Date:7/31/2014)... Calif. , July 31, 2014 Rogne ... San Francisco Bay Area , has acquired a ... of Oxford,s commercialisation company. The potent anti-inflammatory activity of ... at the University of Oxford,s Sir William ... company, which has raised over $1.5 million in seed ...
(Date:7/31/2014)... 2014 Research and Markets has ... 2014-2018" report to their offering. ... study of the genetic material or genomes of an ... for the discovery and development of diagnostic and therapeutic ... conditions. Genomics is supported by three major product segments: ...
Breaking Biology Technology:Research on Digital Health, Alzheimer's, Ebola Draws Nearly 20,000 Attendees to 2014 AACC Annual Meeting & Clinical Lab Expo 2Research on Digital Health, Alzheimer's, Ebola Draws Nearly 20,000 Attendees to 2014 AACC Annual Meeting & Clinical Lab Expo 3New mapping approach lets scientists zoom in and out as the brain processes sound 2Oxford licenses anti-inflammatory peptides to San Francisco Bay Area start-up 2Oxford licenses anti-inflammatory peptides to San Francisco Bay Area start-up 3Global Genomics Market 2014-2018: Key Vendors are F. Hoffmann-La Roche, Life Technologies, Qiagen and Illumina 2
... BOULDER, Colo., and IPSWICH, Mass., July 27, ... Biolabs, Inc. (NEB) announce today that they ... whereby SomaLogic will provide specific SOMAmers as ... and future NEB nucleic acid amplification and ...
... July 27, 2011 Cadence Pharmaceuticals, Inc. (NASDAQ: ... and commercializing proprietary products principally for use in the hospital ... ended June 30, 2011 financial results on Wednesday, August 3, ... call and live webcast to discuss the financial results on ...
... Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ) today ... registration trial of KRX-0401 (perifosine) for the treatment of ... over 430 randomized patients, is being conducted pursuant to ... Drug Administration (FDA) and with Fast-Track Designation.  Perifosine is ...
Cached Biology Technology:Agreement Between SomaLogic and New England Biolabs Enables the Use of SOMAmer Technology for the Optimization of Multiple PCR Products 2Keryx Biopharmaceuticals Announces Completion of Patient Enrollment in KRX-0401 (Perifosine) Phase 3 Refractory Advanced Colorectal Cancer Study 2Keryx Biopharmaceuticals Announces Completion of Patient Enrollment in KRX-0401 (Perifosine) Phase 3 Refractory Advanced Colorectal Cancer Study 3Keryx Biopharmaceuticals Announces Completion of Patient Enrollment in KRX-0401 (Perifosine) Phase 3 Refractory Advanced Colorectal Cancer Study 4Keryx Biopharmaceuticals Announces Completion of Patient Enrollment in KRX-0401 (Perifosine) Phase 3 Refractory Advanced Colorectal Cancer Study 5
(Date:7/31/2014)... study (HPV-023; NCT00518336) shows the sustained efficacy, ... virus (HPV) vaccine Cervarix. Women vaccinated with ... more than nine years, and vaccine efficacy ... is the longest follow-up report for a ... for the full paper. , HPV ...
(Date:7/31/2014)... experimental vaccine protected 100 percent of animal models against ... , which causes an intestinal disease that kills approximately ... print in Infection and Immunity . , ... non-human primates against the purified toxins produced by ... spore infection, a laboratory model that mimics the human ...
(Date:7/31/2014)... BOZEMAN, Mont. In the same week that the ... dangers of skin cancer, researchers at Montana State University ... the genetic code in every cell responds ... advance fundamental understanding of DNA damage by the UV ... skin cancer, aging and some degenerative eye diseases. ...
Breaking Biology News(10 mins):Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 2Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 3C. difficile vaccine proves safe, 100 percent effective in animal models 2New paper describes how DNA avoids damage from UV light 2New paper describes how DNA avoids damage from UV light 3
... The effects of fruit and vegetable consumption on ... origin, according to a new study published in the ... Dietetic Association . Researchers found that within the proximal ... and broccoli) were associated with decreased risk of these ...
... instinctive but is a skill that birds learn from ... Weaver birds in Botswana as they built multiple nests ... contrast with the commonly-held assumption among scientists that nest-building ... individual birds varied their technique from one nest to ...
... time discovered sixteen new sections of the genetic code that ... for better prevention as well as treatment for lung diseases. ... in Europe, the USA and Australia identified genetic variants associated ... sheds new light on the molecular basis of lung diseases ...
Cached Biology News:Fruits and vegetables reduce risks of specific types of colorectal cancers 2New discoveries in genetics of lung health 2
... contains sufficient materials for 1,464 array sample elements. ... , Blocker BSA in PBS (10X): ... HRP-conjugated: 10 g , BupH Phosphate ... Tween-20: 2 x 10 ml ampules , SuperSignal ...
... The Partec Cell Counter Analyser counts ... that the CCA detects only cells, so ... influence the results.,While passing through a 250 ... a fluorescence light signal which is used ...
... system, 100-120 V, is used for biolistic ... handheld device employs an adjustable helium pulse ... gold microcarriers from the inner wall of ... cells. This system has a 2 square-centimeter ...
... Results Laser Capture Microdissection (LCM) enables ... accuracy of molecular assays by starting with ... structures isolated from whole tissue or cytology ... 1996 at the National Institutes of Health ...
Biology Products: